Issue : The Pharmaceutical Journal, 25 July/1 August 2015, Vol 295, No 7872/3
Sort by: Newest first Oldest first A-Z Z-A
-
Progesterone receptor could slow breast cancer growth Subscription
Researchers have discovered why breast cancer patients whose tumours display both oestrogen and progesterone receptors have the best chance of survival.
-
Tuesday 8 September: RPS Faculty webinar Subscription
Royal Pharmaceutical Society (RPS) Faculty webinar, ‘You, your professional practice and the Faculty’. Learn about how using the Faculty assessment supports your professional practice. Find out how the Faculty supports the forthcoming continuing fitness to practise requirements; provides evidence ...
-
Robert Lees dies Subscription
On 10 July 2015, Robert Lees FRPharmS, aged 88, of Sudbury, Suffolk. Mr Lees registered with the Society in 1949.
-
New indication for Simponi Subscription
According to the updated summary of product characteristics (SPC), Simponi (golimumab; Merck Sharp & Dohme) is now indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein or magnetic resonance imaging evidence or both, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs. Further changes to the SPC reflect this ...
-
MenACWY vaccine in Wales Subscription
A combined vaccine that protects against the A,C,W and Y strains of meningococcal disease (MenACWY) is being introduced in Wales, replacing the existing meningitis C jab. From August 2015, the vaccine will be offered to all students aged under 25 years who are attending university for the first time this autumn. There will also be a catch-up programme for all 14–18 year olds over the next two years.
-
Increase in harm from synthetic cannabinoid use Subscription
Public Health England has published a notice alerting healthcare professionals to the recent increase in harm caused by synthetic cannabinoid use. The notice provides some examples of available synthetic cannabinoids and describes the symptoms that may arise from acute toxicity. It is available from Central Alerting System ...
-
Medical benefits of cannabis can be separated from unwanted side effects Subscription
Scientists have found that inhibiting the effects of a certain receptor in the brains of mice can prevent negative effects of cannabis but keeps benefits such as pain relief.
-
‘Debranding’ of branded products Subscription
For some years now, certain manufacturers have been removing the brand name of a medicine and relaunching the product as a generic — so called “debranding”. The aim of this exercise is to circumvent the Pharmaceutical Price Regulation Scheme (PPRS) and allow the manufacturer to increase the price to the NHS.
-
Fish oil and antioxidants help clear Alzheimer’s proteins in brains of people without the disease Subscription
A study finds that supplements can help clear amyloid-β protein, which accumulates in the brain during Alzheimer’s disease, but only in patients with minor cognitive impairment or no disease.
-
FDA approves brexpiprazole for schizophrenia and depression Subscription
The US Food and Drug Administration has approved brexpiprazole for the treatment of adults with schizophrenia and as add-on therapy in patients with major depressive disorder.
Show 10 per page20 per page50 per page
